Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease

被引:11
|
作者
Carricarte Naranjo, Claudia [1 ]
Marras, Connie [2 ,3 ]
Visanji, Naomi P. [2 ,3 ]
Cornforth, David J. [4 ]
Sanchez-Rodriguez, Lazaro [5 ]
Schule, Birgitt [6 ]
Goldman, Samuel M. [7 ]
Estevez, Mario [8 ]
Stein, Phyllis K. [9 ]
Lang, Anthony E. [2 ,3 ]
Jelinek, Herbert F. [10 ]
Machado, Andres [1 ]
机构
[1] Univ La Habana, Fac Biol, Calle 25 455,Plaza Revoluc, Havana 10400, Cuba
[2] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, 399 Bathurst St, Toronto, ON M5T 2S8, Canada
[3] Toronto Western Hosp, Gloria Shulman Movement Disorders Clin, 399 Bathurst St, Toronto, ON M5T 2S8, Canada
[4] Univ Newcastle, Sch Elect Engn & Comp, Univ Dr, Callaghan, NSW 2308, Australia
[5] Univ Calgary, Dept Radiol, 330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada
[6] Stanford Sch Med, Dept Pathol, 300 Pasteur Dr,R271, Stanford, CA 94305 USA
[7] Univ Calif San Francisco, Dept Neurol, 3333 Calif St, San Francisco, CA 94118 USA
[8] Inst Neurol & Neurocirugia, Dept Neurofisiol Clin, Calle 29 139,Plaza Revoluc, Havana 10400, Cuba
[9] Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA
[10] Charles Sturt Univ, Sch Community Hlth, Elizabeth Mitchell Dr, Albury, NSW 2640, Australia
基金
加拿大健康研究院;
关键词
Autonomic dysfunction; Heart rate variability; Parkinson's disease; LRRK2; Deceleration capacity of heart rate; Renyi entropy; HEART-RATE-VARIABILITY; AUTONOMIC CONTROL; DECELERATION CAPACITY; MYOCARDIAL-INFARCTION; STIMULATION; ABNORMALITIES; DYSFUNCTION; MUTATIONS; PHENOTYPE; MORTALITY;
D O I
10.1007/s10286-019-00632-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Cardiac autonomic dysfunction manifests as reduced heart rate variability (HRV) in idiopathic Parkinson's disease (PD), but no significant reduction has been found in PD patients who carry the LRRK2 mutation. Novel HRV features have not been investigated in these individuals. We aimed to assess cardiac autonomic modulation through standard and novel approaches to HRV analysis in individuals who carry the LRRK2 G2019S mutation. Methods Short-term electrocardiograms were recorded in 14 LRRK2-associated PD patients, 25 LRRK2-non-manifesting carriers, 32 related non-carriers, 20 idiopathic PD patients, and 27 healthy controls. HRV measures were compared using regression modeling, controlling for age, sex, mean heart rate, and disease duration. Discriminant analysis highlighted the feature combination that best distinguished LRRK2-associated PD from controls. Results Beat-to-beat and global HRV measures were significantly increased in LRRK2-associated PD patients compared with controls (e.g., deceleration capacity of heart rate: p = 0.006) and idiopathic PD patients (e.g., 8th standardized moment of the interbeat interval distribution: p = 0.0003), respectively. LRRK2-associated PD patients also showed significantly increased irregularity of heart rate dynamics, as quantified by Renyi entropy, when compared with controls (p = 0.002) and idiopathic PD patients (p = 0.0004). Ordinal pattern statistics permitted the identification of LRRK2-associated PD individuals with 93% sensitivity and 93% specificity. Consistent results were found in a subgroup of LRRK2-non-manifesting carriers when compared with controls. Conclusions Increased beat-to-beat HRV in LRRK2 G2019S mutation carriers compared with controls and idiopathic PD patients may indicate augmented cardiac autonomic cholinergic activity, suggesting early impairment of central vagal feedback loops in LRRK2-associated PD.
引用
收藏
页码:603 / 614
页数:12
相关论文
共 50 条
  • [1] Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson’s disease
    Claudia Carricarte Naranjo
    Connie Marras
    Naomi P. Visanji
    David J. Cornforth
    Lazaro Sanchez-Rodriguez
    Birgitt Schüle
    Samuel M. Goldman
    Mario Estévez
    Phyllis K. Stein
    Anthony E. Lang
    Herbert F. Jelinek
    Andrés Machado
    Clinical Autonomic Research, 2019, 29 : 603 - 614
  • [2] Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease
    Arora, Siddharth
    Visanji, Naomi P.
    Mestre, Tiago A.
    Tsanas, Athanasios
    AlDakheel, Amaal
    Connolly, Barbara S.
    Gasca-Salas, Carmen
    Kern, Drew S.
    Jain, Jennifer
    Slow, Elizabeth J.
    Faust-Socher, Achinoam
    Lang, Anthony E.
    Little, Max A.
    Marras, Connie
    JOURNAL OF PARKINSONS DISEASE, 2018, 8 (04) : 503 - 510
  • [3] Heart Rate Variability in leucine-rich repeat kinase 2-Associated Parkinson's Disease
    Visanji, Naomi P.
    Bhudhikanok, Grace S.
    Mestre, Tiago A.
    Ghate, Taneera
    Udupa, Kaviraj
    AlDakheel, Amaal
    Connolly, Barbara S.
    Gasca-Salas, Carmen
    Kern, Drew S.
    Jain, Jennifer
    Slow, Elizabeth J.
    Faust-Socher, Achinoam
    Kim, Sam
    Valappil, Ruksana Azhu
    Kausar, Farah
    Rogaeva, Ekaterina
    Langston, J. William
    Tanner, Caroline M.
    Schule, Birgitt
    Lang, Anthony E.
    Goldman, Samuel M.
    Marras, Connie
    MOVEMENT DISORDERS, 2017, 32 (04) : 610 - 614
  • [4] Effects of sevoflurane on leucine-rich repeat kinase 2-associated Drosophila model of Parkinson's disease
    Shan, Zhiming
    Cai, Song
    Zhang, Tao
    Kuang, Liting
    Wang, Qi
    Xiu, Huanhuan
    Wen, Jing
    Gu, Huaiyu
    Xu, Kangqing
    MOLECULAR MEDICINE REPORTS, 2015, 11 (03) : 2062 - 2070
  • [5] Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease
    Naranjo, Claudia Carricarte
    Marras, Connie
    Visanji, Naomi P.
    Cornforth, David J.
    Sanchez-Rodriguez, Lazaro
    Schuele, Birgitt
    Goldman, Samuel M.
    Estevez, Mario
    Stein, Phyllis K.
    Lang, Anthony E.
    Machado, Andres
    Jelinek, Herbert F.
    2020 11TH CONFERENCE OF THE EUROPEAN STUDY GROUP ON CARDIOVASCULAR OSCILLATIONS (ESGCO): COMPUTATION AND MODELLING IN PHYSIOLOGY NEW CHALLENGES AND OPPORTUNITIES, 2020,
  • [6] Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease
    Carricarte Naranjo, Claudia
    Marras, Connie
    Visanji, Naomi
    Cornforth, David
    Sanchez-Rodriguez, Lazaro
    Schuele, Birgitt
    Goldman, Samuel
    Estevez, Mario
    Lang, Anthony
    Jelinek, Herbert
    Machado, Andres
    MOVEMENT DISORDERS, 2018, 33 : S45 - S45
  • [7] Leucine-rich repeat kinase 2 and Parkinson's disease
    Kang, Un-Beom
    Marto, Jarrod A.
    PROTEOMICS, 2017, 17 (1-2)
  • [8] The Prodromal Phase of Leucine-Rich Repeat Kinase 2-Associated Parkinson Disease: Clinical and Imaging Studies
    Pont-Sunyer, Claustre
    Tolosa, Eduardo
    Caspell-Garcia, Chelsea
    Coffey, Christopher
    Alcalay, Roy N.
    Chan, Piu
    Duda, John E.
    Facheris, Maurizio
    Fernandez-Santiago, Ruben
    Marek, Kenneth
    Lomena, Francisco
    Marras, Connie
    Mondragon, Elisabet
    Saunders-Pullman, Rachel
    Waro, Bjorg
    MOVEMENT DISORDERS, 2017, 32 (05) : 726 - 738
  • [9] Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
    West, AB
    Moore, DJ
    Biskup, S
    Bugayenko, A
    Smith, WW
    Ross, CA
    Dawson, VL
    Dawson, TM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (46) : 16842 - 16847
  • [10] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482